SIGN UP

top stories

Can the Pfizer machine fight back against an activist investor?

2 hours ago

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

6 hours ago

Umoja’s $100M Series C will advance its bid for more convenient cell therapies

1 hour ago

Latest

Regenxbio sells Hunter syndrome license with FDA filing underway

1 hour ago

Australia's BioCina and NovaCina join forces to make one CDMO

2 hours ago

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

2 hours ago

FTC goes after pharma middlemen's price hikes on 'specialty' drugs

2 hours ago

see latest stream

People

Exclusive: Day after GSK buyout, IDRx chair takes new investing role at Curie.Bio

5 hours ago

Gottlieb says RFK Jr. as HHS secretary could bring ‘tragic’ outbreaks

22 hours ago

Post-Hoc: Big Pharma is losing the AI talent war

3 days ago

Financing

Health tech funding in 2025 kicks off with megarounds

7 hours ago

Normunity nabs $75M Series B to advance T cell engager and launch first trial

Yesterday

Aragen gets $100M from private equity firm to expand manufacturing footprint

Yesterday

Startups

Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo

Yesterday

Chasing the next wave of obesity drugs, Metsera files for an IPO

3 days ago

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

4 days ago

Deals

Daiichi Sankyo brings Glycotope antibody in-house for $132.5M

6 hours ago

AstraZeneca, CRISPR tools supplier ink gene editing enzyme licensing deal

Yesterday

Updated: J&J to buy Intra-Cellular for $14.6B in latest neuroscience bet

Yesterday

In FocusSee all

How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug prices

4 weeks ago

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Last month

As 23andMe struggles, another genetic testing company bets on drug discovery

Last month

Lawmakers are poking holes in pharma's favorite new way to market medicines

Last month

Endpoints Standouts

How the world's biggest pharma and biotech companies paid their typical worker in 2023

6 months ago

In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

6 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

6 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

6 months ago

Peer review See all

Jan

10

John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief

Dec

20

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO

Dec

13

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Dec

6

Mark Alles’ ADC bet TORL poaches J&J medical exec; Samsung Bioepis makes historic CEO appointment

Nov

22

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Pharma channel feed

22 hours ago

Moderna lowers 2025 revenue estimate, announces more cost cuts

Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle with a slow RSV launch and a shaky Covid-19 vaccine market.

READ MORE

Federal Circuit upholds Novartis patent for heart drug Entresto

23 hours ago

AbbVie partners with Simcere Pharma unit to develop myeloma drug

Yesterday

latest in Pharma

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share perspectives

Yesterday

J&J looks at potential bid for Intra-Cellular — report

Yesterday

FDA adcomm votes to support Seikagaku's herniated disc injection

3 days ago

Lawmakers ask Biden administration to tighten rules around China clinical trials

3 days ago

Pfizer touts bladder cancer results as first advancement for some patients 'in decades'

3 days ago

see latest stories

Marketing channel feed

Last week

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival in a Phase 3 trial, notching a key win in its rivalry against ...

READ MORE

Drugs are approved — and made available — faster in US than most of EU, data show

Last month

Novartis bolsters Fabhalta data in competition with AstraZeneca

Last month

latest in Marketing

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Last month

FDA says Merz's social media promotion with Nate Berkus is 'misleading'

2 months ago

Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine

3 months ago

UK watchdog criticizes Moderna for Covid-19 trial's use of WhatsApp to dangle payments to children

3 months ago

FDA criticizes AbbVie's 'misleading' ad with Serena Williams

4 months ago

see latest stories

FDA+ channel feed

21 hours ago

BIO CEO plans to join FDA modernization advisory board under Trump administration

John Crowley, CEO of the biotech advocacy group BIO, is slated to join a Trump administration advisory board focused on modernizing the FDA, according to a source familiar with the ...

READ MORE

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

4 days ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

4 days ago

latest in FDA+

Catalyst staves off Firdapse competition from Teva for a decade

4 days ago

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

5 days ago

Ahead of adcomm, FDA discusses Seikagaku's mixed trial results for its lumbar disc herniation injection

5 days ago

After a bump in adcomms in 2023, FDA advisory panels returned to 2022 levels

6 days ago

FDA sets an efficacy threshold for future weight loss drugs

6 days ago

see latest stories

Manufacturing channel feed

5 days ago

Samsung Bio extends ADC partnership; Veeda rebrands as CDMO

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

READ MORE

Synaffix adds Boehringer and Mitsubishi Tanabe as ADC licensing partners

5 days ago

Resilience cuts 120 employees at a former bluebird gene therapy site

6 days ago

latest in Manufacturing

BWX Technologies to buy Canadian isotope maker for $525M

Last week

Anthem Biosciences eyes $397M public offering in India

Last week

WuXi Biologics to sell Irish vaccine site to Merck for $500M

Last week

WuXi AppTec will sell cell and gene therapy business to private equity firm

3 weeks ago

Lonza expands capsule footprint; BioCentriq's new HQ

4 weeks ago

see latest stories